This post-market study follows the successful completion of its REPRISE II clinical trial, which reported strong performance results for the TAVR system in terms of safety and efficacy at six months, according to data presented by the company at EuroPCR 2014 in Paris last month.
Source: Markets
Author
Harry Joiner
“… a dominant recruiter in the client-side multichannel ecommerce space …” — SearchEngineWatch.com